Trials / Terminated
TerminatedNCT02223598
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Cleave Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CB-5083 | |
| DRUG | Dexamethasone |
Timeline
- Start date
- 2014-08-25
- Primary completion
- 2017-07-26
- Completion
- 2017-07-26
- First posted
- 2014-08-22
- Last updated
- 2018-02-27
Locations
8 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02223598. Inclusion in this directory is not an endorsement.